Susan Berland - Senti Biosciences Senior Director

SNTI Stock  USD 2.14  0.03  1.42%   

Director

Susan Berland is Senior Director of Senti Biosciences
Age 69
Phone650 239 2030
Webhttps://www.sentibio.com

Susan Berland Latest Insider Activity

Tracking and analyzing the buying and selling activities of Susan Berland against Senti Biosciences stock is an integral part of due diligence when investing in Senti Biosciences. Susan Berland insider activity provides valuable insight into whether Senti Biosciences is net buyers or sellers over its current business cycle. Note, Senti Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Senti Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Senti Biosciences Management Efficiency

The company has return on total asset (ROA) of (0.3302) % which means that it has lost $0.3302 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1107) %, meaning that it created substantial loss on money invested by shareholders. Senti Biosciences' management efficiency ratios could be used to measure how well Senti Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.
Senti Biosciences currently holds 37.67 M in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. Senti Biosciences has a current ratio of 7.93, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Senti Biosciences' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 3 records

DIRECTOR Age

Michele GruberLipella Pharmaceuticals Common
N/A
Adrian HaighFennec Pharmaceuticals
65
Zheng WeiConnect Biopharma Holdings
60
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. The company was incorporated in 2016 and is headquartered in South San Francisco, California. Senti Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. Senti Biosciences (SNTI) is traded on NASDAQ Exchange in USA. It is located in 2 Corporate Drive, South San Francisco, CA, United States, 94080 and employs 48 people. Senti Biosciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Senti Biosciences Leadership Team

Elected by the shareholders, the Senti Biosciences' board of directors comprises two types of representatives: Senti Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Senti. The board's role is to monitor Senti Biosciences' management team and ensure that shareholders' interests are well served. Senti Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Senti Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Dee Dragon, Vice Culture
Thomas Chung, Vice Development
Susan Kahlert, Controller
Kanya MD, Head President
Yvonne MBA, Treasurer CFO
James Collins, Chairperson CoFounder
Wilson Wong, Scientific Board
Deborah Knobelman, CFO Treasurer
Philip Lee, CoFounder CTO
Susan Berland, Senior Director
Mike Rhee, General Secretary

Senti Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Senti Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Senti Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Senti Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Senti Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Senti Biosciences Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Senti Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Senti Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.